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Abstract: This review article summarizes the main treatments for chronic obstructive pulmonary disease, their mechanisms, and the 
key evidence from trials supporting their use. Drug classes covered were short acting beta agonists (SABA), short acting muscarinic 
antagonists (SAMA), long acting beta agonists (LABA), long acting antimuscarinics (LAMA), inhaled corticosteroids (ICS), LABA/
ICS combinations, specific phosphodiesterase (PDE4) inhibitors, non-specific PDE inhibitors, mucolytics, and oxygen. Non-specific 
therapies, such as opiates for relief of dyspnoea and therapies for smoking cessation, are also covered briefly. For each class of drug, 
mechanisms of action are described, key clinical trial results are reported, and available agents compared. Finally, the place of each drug 
in therapy is compared between current worldwide guidelines.
Keywords: chronic obstructive pulmonary disease, pharmacotherapies, disease management
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Introduction
Chronic obstructive pulmonary disease (COPD) is a 
multi-component disease which is both preventable 
and treatable. It is currently the fourth leading cause 
of death worldwide and predicted to be the third by 
2020.1 Globally the burden of disease is projected to 
increase in the coming decades due to continued expo-
sure to COPD risk factors and an ageing population.1
COPD is characterized by airflow limitation that is 
progressive and not fully reversible; the latest sever-
ity categorization also includes exacerbation frequency 
and symptom burden as key features.1 COPD is associ-
ated with an enhanced chronic inflammatory response 
which is responsible for the airway abnormalities and 
architectural distortion of the lung parenchyma. In 
affected individuals lung function deteriorates pro-
gressively over several years, with increasing symp-
toms such as cough, sputum production, and dyspnoea. 
Acute exacerbations are defined by increased cough, 
dyspnea, or increased sputum purulence from baseline,2 
and punctuate the disease process with a deleterious 
impact on patients’ daily activities and well-being.3 
Frequent exacerbations are associated with more rapid 
decline of lung function4 and are one of the greatest 
costs to the health economy, partly through hospital 
admissions, and partly through loss of work days.5 
Although mainly categorized by airflow limitation, 
in many patients the disease seems to be associated 
with several extra-pulmonary manifestations. What is 
unclear at present is whether these manifestations are 
directly related to COPD or are just an independent 
consequence of the exposure to common causal effects 
such as tobacco smoking and inactivity. The most 
widely recognized manifestations include the presence 
of concomitant cardiovascular disease, skeletal mus-
cle dysfunction, osteoporosis, and clinical depression/
anxiety.6 These co-morbidities interact to increase the 
risk of hospitalization and mortality in COPD patients, 
especially as the airway obstruction becomes more 
severe.7 The main goals in management of COPD are 
improving health status, reducing symptoms, preserv-
ing lung function decline, preventing exacerbations, 
and reducing mortality. This review outlines the phar-
macological management of stable COPD.
Bronchodilators
Dyspnoea is one of the hallmark symptoms of COPD 
and one of the most common reasons for health 
resource utilization and increasing anxiety in affected 
patients.8 Dynamic hyperinflation as a result of 
increased lung volumes is a key reason why patients 
experience dyspnoea. Long acting bronchodilators 
reduce lung volumes by a reduction in air trapping 
and facilitate the emptying of the lungs.9 The subse-
quent improvement in inspiratory capacity leads to 
reduced dyspnoea and improved exercise tolerance.8 
The available long acting bronchodilators include B2 
agonists and anti-muscarinics.
Beta 2 adrenoceptor agonists 
(B2-agonists)
Mechanism of action
B2 adrenergic receptors (B2AR) are present in high den-
sity in airway smooth muscle cells. B2 agonists act by 
binding to the B2AR (Fig. 1). Interaction of the recep-
tor with intracellular G proteins stimulates the produc-
tion of intracellular cyclic adenosine monophosphate 
(cAMP). This leads to activation of protein kinase A, 
which results in phosphorylation of various targets 
mediating smooth muscle relaxation. The exact targets 
are unknown but probably involve myosin light chain 
kinase and calcium dependent potassium channels.10
B2AR are also present in vascular endothelium, 
ciliated cells, circulating inflammatory cells (such as 
eosinophils), and sub-mucosal glands. The presence 
of the receptor on these cells explains some of the non-
bronchodilator effects, including attenuation of mast 
cell mediator release, reduction of plasma exudation, 
and reduced activation of sensory nerves. Other ben-
eficial effects include enhancement of mucociliary 
transport,11 attenuation of neutrophil recruitment,12 
and inhibition of smooth muscle cell proliferation.13
Beta receptor
GDP GTP
Adenyl
cyclase
Agonist
ATP cAMP
Protein
kinase ABiologic effects
GTP GDP
Figure 1. Mechanism of action of Beta agonists.
notes: Binding of the agonist to the receptor results in a change in 
protein structure, which enables interaction with intracellular G proteins, 
production of cAMP and then protein kinase A, which mediates the 
bronchodilating effects via its actions on smooth muscle.
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Short acting B2AR agonists (SABAs)
Although many patients with COPD do not have 
reversible airflow obstruction, many have noted 
symptomatic improvement with the use of SABAs.14 
SABAs are used both in acute and chronic man-
agement of COPD, the most commonly used being 
Salbutamol. Once administered, the onset of action 
is within 3 minutes with peak activity after 2.5 hours. 
The duration of action is between 4 and 6 hours.15 
Salbutamol is mainly metabolized to a sulphate con-
jugate. Approximately 50% is excreted in this form 
with a smaller proportion as unchanged drug.16 The 
most recent Cochrane review showed that use of 
SABAs for at least seven days improved post bron-
chodilator lung function in patients with moderate to 
severe COPD. Patients were also less dyspnoeic and 
more likely to comply with treatment.14
Long acting B2AR agonists (LABAs)
This class of drug has recently been reviewed and com-
pared to one of the long acting anti-muscarinic agents 
(LAMAs) by the Cochrane collaboration,17 although 
significant trial heterogeneity precluded meta-
 analysis, primarily due to the fact that  indacaterol’s 
effect on health related quality of life (HRQoL) in 
particular differed from the other LABAs. Most of 
the primary studies of LABAs did not have exac-
erbation frequency as a primary outcome measure, 
although meta-analysis of their data has been carried 
out;18 in general there is a class effect showing reduc-
tion in exacerbations against placebo. Their place in 
therapy is generally considered as one of the options 
for maintenance therapy in patients that are symptom-
atic despite regular SABA use;1 treatment algorithms 
for the disease will be considered at the end of this 
article.
Salmeterol and formoterol
Salmeterol and formoterol are LABAs with 
extended duration of action maintained 12 hours 
after inhalation of a single dose,19 which has led to 
their twice daily dosing. Formoterol’s potency and 
speed of action make it effective in both quick relief 
and for prolonged effect. Despite these characteris-
tics, it appears to be inferior to salmeterol in terms 
of health related quality of life (HRQoL) scores and 
its ability to reduce exacerbations, albeit in indirect 
comparisons only.17 Salmeterol and  formoterol have 
some important differences which can be explained 
by their physicochemical  properties. Both are 
lipophilic, with salmeterol being far more so than 
formoterol; the relative water solubility of formot-
erol enables it to diffuse rapidly to the B2AR and 
cause bronchodilation in between 1 to 3 minutes, 
similar to that of SABAs.20  Salmeterol’s onset of 
action is, at least 20 minutes, significantly  longer.21 
Both drugs have adequate lipophilic properties 
that allow them to remain in the airway tissues in 
close vicinity to B2AR, explaining the longer dura-
tion of action. There is also some evidence to sug-
gest that salmeterol binds to an additional exosite 
within the receptor, potentiating the longer effect 
of the drug.22 Secondly the intrinsic efficacy of 
the drugs varies—formoterol is a full agonist 
whilst salmeterol is a partial agonist; hypotheti-
cally this implies formoterol should provide better 
bronchodilation.
Salmeterol xinafoate dissociates in solution to 
 salmeterol and 1-hydroxy-2-naphthoic acid. These 
two compounds are then absorbed, distributed, 
metabolized, and excreted independently. The xin-
afoate moiety has no discernable  pharmacological 
activity, is highly protein bound, and has a long 
elimination half-life of about 12 to 15 days in 
healthy  individuals. The cytochrome P450 (CYP) 
isoform 3A4 is responsible for aliphatic oxidation 
of salmeterol base, which is extensively metabo-
lized by hydroxylation, with the major metabolite 
being alpha- hydroxysalmeterol and with subsequent 
elimination predominantly in the feces.23  Formoterol 
is metabolized primarily in the liver by CYP450 
enzymes and undergoes glucuronidation and 
O-demethylation. Elimination of formoterol is via 
the urine and feces in ratios of two thirds and one 
third respectively, with 10% of urinary excretion 
being of unchanged drug.24
Clinical trials pertaining to the efficacy of formot-
erol and salmeterol are shown in Table 1. Whilst no 
head to head trials of the 2 agents have been done, 
indirect comparison within the Cochrane review17 
suggests that their effects are largely the same. 
 Additionally, reduction in exacerbation rate was not 
maintained in patients on inhaled corticosteroids 
(ICS) and formoterol, unlike the other LABAs.18
Indacaterol is an ultra-long acting, once daily 
LABA; it is the only agent of this type currently on the 
Ejiofor and Turner
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Table 1. Major randomized controlled trials (RCTs) of salmeterol and formoterol.
Trial Duration Outcome comparator
salmeterol
Boyd et al25 16 weeks ↑ FEv1 Placebo
Mahler et al26 12 weeks ↑ FEv1 Placebo, ipratropium*
Rennard et al27 12 weeks ↑ FEv1 Placebo
Calverley et al28 
(TRISTAN)
1 year ↑ FEv1
↓ Exacerbations
↑ HRQoL
Placebo, fluticasone, 
fluticasone/salmeterol
Calverley et al29 
(TORCH)
3 years ↑ FEv1
↓ Exacerbations
↑ HRQoL
Placebo, fluticasone, 
salmeterol/fluticasone
Formoterol
Dahl et al30 12 weeks ↑ FEv1
↓ Symptom scores
Placebo, ipratropium*
De Rossi et al31 1 year ↑ FEv1 Placebo, theophylline*
Calverley et al32 1 year ↔ FEv1
↑ HRQoL
Placebo, budesonide, 
budesonide/formoterol
Szafranski et al33 1 year ↔ FEv1
↔ HRQoL
Placebo, budesonide, 
budesonide/formoterol
notes: The table shows results against placebo; for results of the multicomponent trials against ICS and ICS/LABA please see text in relevant section. 
*Also significant result against active comparator.
market, although others are in development,  including 
vilanterol.34 It is a partial B2 agonist which exhibits 
high intrinsic efficacy at the B2AR, more than two fold 
that of salbutamol and salmeterol.35 Partial agonists can 
exhibit antagonist behavior in the presence of an ago-
nist with higher receptor efficacy, which could poten-
tially result in inhibitory action of rescue medication, 
an effect which has been shown with salmeterol but 
not indacaterol.35 Studies using indacaterol have dem-
onstrated a relatively rapid onset of action (5 minutes) 
with peak effect occurring at 15 minutes and lasting 
24 hours.35 The rapid onset of action and length of 
duration of action is related to both the high affinity of 
indacaterol to the lipid raft domains within the B2AR 
membrane and its intrinsic efficacy at the receptor 
 level.35 Following administration, the bioavailability of 
indacaterol is 43%, with a steady state reached after 12 
to 14 days. It is primarily metabolized to a hydroxylated 
derivate by the CYP3A4 enzyme, and subsequent to 
this, to phenolic O glucuronides and other  metabolites. 
Elimination occurs via the fecal route, with less than 
2% being excreted unchanged in the urine.35
The clinical trials pertaining to indacaterol’s effi-
cacy are shown in Table 2. Current evidence sug-
gests that indacaterol is superior to other LABAs 
with regard to HRQoL.17 Sub-group analyses with 
regard to  exacerbations showed that indacaterol had 
a greater effect on severe exacerbations (ie, hospi-
talized event rate).18
Safety
In general, apart from the occasional episode of tachy-
cardia and tremor, both SABAs and LABAs are well 
tolerated. However, here has been some concern with 
regard to cardiovascular safety and use of B2 agonists. 
Salpeter et al41 suggested increased cardiovascular 
risk with LABAs compared with placebo, a fact hotly 
debated but disproven in subsequent meta-analyses 
in COPD.42 It has also been suggested that tolerance/
tachyphylaxis would render LABAs less efficacious 
over time. Data from Szafranski et al33 and TORCH29 
has refuted this by demonstrating that the bronchodi-
lator effect of LABA therapy is maintained at 1 and 3 
years respectively.
Muscarinic antagonists
Mechanism of action
Para-sympathetic activity mediates both bronchial 
smooth muscle contraction and the release of mucus 
into the airway lumen through stimulation of musca-
rinic receptors, of which there are five distinct types 
(M1–M5).43 Whilst the role of subtypes M4 and 
M5 are unknown, subtypes M1–M3 are expressed 
in human lungs. M1 receptors are expressed in 
COPD pharmacotherapies
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Table 2. Major RCTs for indacaterol.
Trial Duration Outcome comparator
Donohue et al36
(INHANCE)
26 weeks ↑ HRQoL
↓ Dyspnoea (TDI)
Placebo, 
tiotropium
Dahl et al37
(INvOLvE)
I year ↑ Bronchodilation (FEv1)
↑ HRQoL
↓ Dyspnoea (TDI)
Prolonged time to exacerbation
Placebo, 
formoterol
Buhl et al38
(INTENSITY)
12 weeks ↔ Bronchodilation (FEv1)
↑ HRQoL
↓ Dyspnoea (TDI)
Tiotropium
Kornmann et al39
(INLIGHT-2)
12 weeks ↑ Bronchodilation (FEv1)
↑ HRQoL
↓ Dyspnoea (TDI)
Placebo, 
salmeterol
Korn et al40
(INSIST)
12 weeks ↑ Bronchodilation (FEv1)
↓ Dyspnoea (TDI)
Salmeterol
notes: The outcomes shown in the table are against the active comparator; good efficacy was also shown against placebo where this arm was used.
Abbreviations: TDI, transitional dyspnoea index.
Smooth muscle
fibre
Preganglionic
parasympathetic
nerve
Post ganglionic
parasympathetic
nerve
M1 receptors
M2 receptors
M3 receptors
Figure 2. Location of anti-muscarinic receptors.
notes: M1 receptors are expressed in peribronchial ganglia, whilst M3 are 
present on bronchial smooth muscle cells; both mediate bronchomotor 
tone and reflex bronchoconstriction. M2 receptors are located in the post 
ganglionic para-sympathetic nerve and act as auto receptors. The figure 
shows their relationship to one another.
Adapted from Lipson DA (2006).
 peribronchial ganglia, whilst M3 receptors are pres-
ent on bronchial smooth muscle cells; their rela-
tionship to one another is shown in Figure 2. Both 
mediate bronchomotor tone and reflex bronchoc-
onstriction. M2 receptors are located in the post 
ganglionic para-sympathetic nerve and act as auto 
receptors.  Agonistic stimulation of these receptors 
provides feedback and inhibition of further ace-
tylcholine release; thus, optimal inhibition of the 
parasympathetic pathway would be achieved by 
selectively blocking M1 and M3 receptors.43
Short acting muscarinic antagonists (SAMAs)
Short acting muscarinic antagonists, like SABAs, 
are used both in the acute and chronic management 
of COPD. Ipratropium bromide is the most widely 
used following the discontinuation of Oxitropium 
bromide in 2004. Ipratropium blocks all muscarinic 
receptors without sub-type selectivity. Its onset of 
action is within minutes, with peak activity occurring 
between 1 and 2 hours and duration of action approx-
imately 4 hours in the majority of patients.43 In a 
systematic review, combination of LABAs with ipra-
tropium showed a small benefit in pre bronchodilator 
FEV1 of borderline statistical significance;
14 however, 
for the most part LABAs were superior. Head to head 
comparison suggested that tiotropium was superior,44 
and thus current guidance places LAMA ahead of 
SAMA for maintenance therapy.5
Long acting muscarinic antagonists (LAMAs)
In general, the place of LAMAs in therapy is the same 
as LABAs. Until recently there was only one LAMA 
on the market (tiotropium), but two other products 
have recently been licensed (glycopyrronium and 
aclidinium). The Cochrane review of LABAs versus 
LAMAs17 was only able to consider trials using tiotro-
pium (due to their search dates) and concluded that its 
effects were superior to LABAs in terms of prevent-
ing exacerbations and disease related hospitalization. 
Nevertheless, drug choice for the individual patient 
may still suggest LABA as a good choice for some, 
ie, in patients with severe glaucoma; thus current 
guidance places the 2 classes of drug equal in ther-
apy algorithms.1,5 Few head to head trials of LAMAs 
Ejiofor and Turner
22 Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 2013:7
have been carried out, with the notable exception of 
GLOW2 (tiotropium versus glycopyrronium),45 which 
concluded that the products were equivalent in terms 
of trough FEV1, dyspnoea score, and exacerbation 
reduction. Aclidinium has been studied alongside 
tiotropium, but this trial was a small study of crossover 
design,46 and therefore larger, more definitive stud-
ies are still needed. A summary of clinical effects, as 
demonstrated by the various LAMA trials, is shown in 
Table 3; since most effects (with the exception of speed 
of onset) appear to be roughly equivalent between the 
3 drugs they have been tabulated together.
Tiotropium
Tiotropium was the first available LAMA and is admin-
istered once daily. It binds to M1–M3 receptors and is 
10 times more potent than ipratropium bromide. It dis-
sociates slowly from M1 and M3 receptors, giving it its 
Table 3. Major RCTs for LAMAs.
Trial Duration Outcome comparator
Tiotropium
Brusasco et al47 26 weeks ↓ Exacerbations
↑ HRQoL
Placebo, 
salmeterol
Briggs et al48 12 weeks ↑ FEv1 Salmeterol*
Tashkin et al49  
(UPLIFT)
4 years ↓ Exacerbations
↑ HRQoL
↑ FEv1
Placebo
vogelmeier et al50  
(POET)
1 year ↓ Exacerbations Salmeterol*
Glycopyrronium
D’Urzo et al51  
(GLOw1)
26 weeks ↑ Trough FEv1
↑ HRQoL
↓ Dyspnoea (TDI score)
↓ Exacerbations
Placebo
Kerwin et al45  
(GLOw2)
1 year Similar to GLOw1 v placebo
↑ Bronchodilation on day 1  
and week 26 v tiotropium
Placebo, 
tiotropium*
Beeh et al8  
(GLOw3)
8 weeks ↑ Endurance time
↑ Inspiratory capacity
Placebo
Aclidinium
Jones et al52  
(ACCLAIM I and II)
1 year ↑ Trough FEv1
↑ HRQoL
Placebo
Jones et al53  
(ATTAIN)
6 months ↑ FEv1
↑ HRQoL
↓ Dyspnoea (TDI)
Placebo
Kerwin et al54  
(ACCORD)
12 weeks ↑ FEv1
↑ HRQoL
↓ Dyspnoea (TDI)
Placebo
Fuhr et al46 15 days per  
treatment
Similar to ACCORD v placebo
↑ Morning FEv1 v tiotropium
Placebo, 
tiotropium
notes: The table shows results against placebo unless otherwise stated. *Also significant result against active comparator.
long acting effect, but dissociates relatively rapidly from 
the M2 receptor, giving it a unique kinetic  selectivity.55 
Once administered the onset of bronchodilation occurs 
within 30 minutes, with peak activity at 3 hours and 
sustained over more than 24 hours.43 Tiotropium has a 
low bioavailability of between 2%–3% and after regu-
lar once daily inhalation, it reaches a steady state after 
2 weeks. The drug is not extensively metabolized but 
the portion that is undergoes hydrolysis into two major 
metabolites, a carboxylic acid derivative and an alcohol 
derivative, neither of which have any affinity for any 
of the muscarinic receptor subtype. A larger proportion 
of the drug is eliminated via renal secretion which means 
there is some accumulation in renal impairment.56
Glycopyrronium
Glycopyrronium is a novel once daily LAMA licensed 
for use in Europe in 2012. Like tiotropium it has a 
COPD pharmacotherapies
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sustained 24 hour bronchodilator effect,45 and higher 
selectivity for the M3 receptor than the M2  receptor.57 
Dissociation from the M3 receptor occurs four times 
faster than tiotropium57 and almost twice as fast as 
 aclidinium.58 This suggests that glycopyrronium 
would have a more rapid onset of action, which has 
been confirmed in clinical studies.45,51  Glycopyrronium 
bromide undergoes mainly hydrolysis, which results 
in the formation of a carboxylic acid derivative, and 
to a lesser extent glucuronidation. Elimination is pre-
dominately via the kidneys.59
Aclidinium bromide
Aclidinium is a recently developed LAMA adminis-
tered twice daily which was approved by the FDA in 
2012. It is a potent and selective muscarinic antago-
nist which displays relative selectivity for the M3 
receptor with a drug/receptor binding rate similar to 
that of ipratropium and 2.6 times faster than that of 
 tiotropium.60 Aclidinium undergoes hydrolysis into 
two major metabolites, a carboxylic acid derivative and 
an alcohol derivative. Owing to its short plasma half-
life and rapid metabolism, very little is excreted in the 
urine, such that no adjustments are required in renal 
disease.61 Once administered, onset of action occurs 
within 15 minutes with a peak activity at 2 hours.60
The clinical trials pertaining to aclidinium’s efficacy 
are shown in Table 4. Potential differences from other 
LAMAs include higher nocturnal FEV1 compared with 
tiotropium, resulting in better morning symptoms.46
Safety
The adverse effects encountered with LAMAs are 
largely those attributed to its anti-cholinergic  activity, 
with dry mouth being one of the most commonly 
reported side effects.49 Clinical trials involving all 
drugs have reported similar adverse event rates with 
the active intervention compared with placebo. In the 
ATTAIN and GLOW2 trials, the most common events 
reported in the aclidinium and glycopyrronium arm 
over placebo were nasopharyngitis.45,53 In the 4 year 
UPLIFT study, the most commonly encountered 
adverse events were due to lower respiratory causes; 
however, this was similar to the placebo arm.49
A study prior to the publication of UPLIFT sug-
gested that use of tiotropium increased cardiovas-
cular morbidity and mortality;62 data from UPLIFT 
refuted this demonstrating a non-significant reduc-
tion in all cause cardiovascular mortality.63 It is of 
note that UPLIFT used the Handihaler device, and 
excluded those with cardiovascular co-morbidity. 
Later analyses of trial data using the Respimat device 
(not licensed in the USA, but available in at least 55 
countries worldwide) still suggested an adverse car-
diovascular mortality effect with tiotropium.64 Much 
debate ensued after this, but a more recent Cochrane 
review65 and a further independent meta-analysis66 
have confirmed the finding of increased mortality 
risk associated with the soft mist inhaler (Respimat). 
Ipratropium and tiotropium are actively transported 
through the bronchial epithelium using the OCTN2 
transporter, which is also present in the human 
heart.67 Furthermore the Respimat device results in 
greater deposition in the lung than the Handihaler.68,69 
Whilst such features may go some way to explaining 
the mechanism of cardiovascular morbidity and it’s 
apparent device specificity, this will require further 
study. In the meantime there has been a call in the UK 
Table 4. Major RCTs of ICS in COPD.
Trial Ics Duration Outcome comparator
Burge et al76 
(ISOLDE)
Fluticasone 1 year ↑ FEv1
↓ Exacerbations
Placebo
Calverley et al23 Budesonide 1 year ↓ Exacerbations*
↑ HRQoL
Placebo, formoterol, 
budesonide/formoterol
Szafranski et al33 Budesonide 1 year ↑ FEv1 Placebo, formoterol, 
budesonide/formoterol
Calverley et al28
(TRISTAN)
Fluticasone 1 year ↑ FEv1
↓ Exacerbations
Placebo, salmeterol, 
salmeterol/fluticasone
Calverley et al29  
(TORCH)
Fluticasone 3 years ↓ Exacerbations
↑ FEv1
Placebo, salmeterol, 
salmeterol/fluticasone
notes: The table shows results for comparisons of ICS against placebo, although many trials used multiple comparators; see text and table in section on 
combined ICS/LABA for other results. *Only exacerbations requiring oral corticosteroids.
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for withdrawal of the Respimat device as a result of 
safety concerns.70
Inhaled corticosteroids
It is clear that ICS reduce airway inflammation, air-
flow limitation, and symptoms in asthma and are 
therefore the mainstay of treatment.71 In COPD, 
however, the role of ICS is more controversial, pre-
dominantly because the pattern of inflammation 
differs. The inflammation in COPD is dominated 
by neutrophilic infiltration, with an increased num-
bers of macrophages and CD8 T lymphocytes; neu-
trophilic infiltration is not as responsive to steroids 
as the eosinophilic inflammation seen in asthma.72 
Despite this, ICS were used in COPD before any real 
evidence of their efficacy was known. Their use in 
COPD has recently been reviewed by the Cochrane 
collaboration, which concluded that although use of 
ICS is associated with a reduction in exacerbation 
rates and possibly a reduced rate of decline in FEV1, 
these benefits need to be weighed against increased 
pneumonia risks and local side effects.73
Mechanism of action
The primary actions of glucocorticoids arise by acti-
vation of specific glucocorticoid receptors (GCR) 
which are found in the cytoplasm of most mammalian 
cell types. The mechanism of action via the GCR is 
shown in Figure 3. Another method by which the GCR 
Cell membrane
GCS
Heat shock proteins
GCR
Steroid response target genes
GREGRE
mRNA
Figure 3. Mechanism of action of ICS.
notes: when a glucocorticoid (GCS) binds to the GCR the heat shock 
proteins are detached resulting in a conformational change and formation 
of a GCR dimer. This dimerization is necessary for the binding of the 
GCR to the glucocorticoid response element (GRE) which is an area of 
DNA responsible for up or down regulating gene expression.
Table 5. Relative therapeutic effects of ICS.
Fluticasone Budesonide
Oral bioavailability (%) ,1 11
Pulmonary deposition (%) 16 28
Receptor binding affinity 1800 935
Protein binding (%) 90 88
Half life (hrs) 7.8 2.8
Clearance (l/h) 69 84
note: 100% is the affinity of dexamethasone, to which the above are 
compared in the table.
 influences inflammatory processes in COPD is the 
interaction between histone deacetylase-2 (HDAC2) 
and nuclear factor kappa B (Nf-kB), a key transcrip-
tion factor. Nf-kB is upregulated in many cell types 
during inflammation and favors the expression of 
pro inflammatory genes. HDAC2 mediated deacety-
lation of the GCR enables it to bind to Nf-kB and 
nullify its effect as a pro inflammatory molecule.74 
HDAC2 modulation is a current area of interest in 
COPD therapy.75 The clinical trials pertaining to the 
efficacy of ICS are shown in Table 5.
Budesonide and fluticasone
Budesonide and fluticasone are the two ICS which 
have been used most extensively in clinical trials per-
taining to COPD. Whilst the potency—and therein 
pharmacological response—of ICS is related to its 
affinity at the GCR, other factors such as particle size 
and pulmonary deposition will determine its thera-
peutic effect. Table 5 outlines the pharmacokinetic 
and pharmacodynamic features of both drugs.77
Budesonide is several times less lipophilic than 
fluticasone and, as a result, dissolves more readily in 
airway mucus and is more rapidly absorbed into the 
airway tissue and systemic circulation. Fluticasone, 
being more lipophilic and thus less water soluble, is 
more likely to be retained in the lumen of the airways; 
it therefore has a greater chance of being removed from 
the airways by mucociliary clearance and cough.78 
Recent studies have shown higher proportions of flu-
ticasone expectorated in the sputum of patient with 
COPD and fluticasone plasma concentration is more 
affected by airflow limitation than budesonide.78
Safety
The adverse effects of ICS are related to its local and 
systemic absorption. The amount of inhaled steroid 
COPD pharmacotherapies
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reaching the systemic circulation is the sum of the 
pulmonary and orally bioavailable fractions. Given 
that most ICS have relatively low oral bioavailability, 
it is largely the absorption from the pulmonary vas-
culature which determines the systemically available 
steroid. Although adrenal suppression is a theoretical 
risk, it has not been reported in COPD, though it has 
been seen in bronchiectasis.79 Local effects, namely 
dysphonia and oral candidiasis. are more frequently 
observed adverse effects demonstrated in the trials in 
Table 4. One of the main concerns in patients using 
ICS is the significantly increased risk of pneumonia 
which was demonstrated in the TORCH trial29 and 
noted in the recent Cochrane review of ICS.73
combination Therapy
There are currently two combination inhalers used in 
the treatment of patients with COPD: Seretide/Advair 
(salmeterol/fluticasone) and Symbicort (budesonide/
formoterol). Both are a combination of a LABA with 
an ICS; thus, for the purposes of this article, the term 
combination therapy is synonymous with these drugs. 
It is important to note that many new combinations 
of drugs are in development for COPD, eg, LABA/
LAMA,80 such that in future we may not use the term 
in the same way. The pharmacokinetics and phar-
macodynamics of the component drugs have been 
discussed in the preceding sections. LABA/ICS com-
binations have been shown to improve lung function 
and HRQoL and to reduce exacerbations in COPD 
patients (Table 6). Current national and international 
guidelines advocate the use of combination inhalers 
in severe and very severe disease.
Synergistic mechanism of action
The two components of ICS/LABA may have an 
additive or synergistic effect; there is greater evidence 
of synergy in allergic inflammation than in COPD 
patients.81 Animal studies suggest that the combina-
tion of ICS plus LABA behaves synergistically,82 
as ICS may regulate the coupling of β receptors to 
G proteins and hence cAMP activation, and overall 
response to LABA. Exposure to exogenous LABA 
(or SABA) leads to uncoupling by phosphorylation of 
the receptor via various pathways, which theoretically 
can lead to drug tolerance. Exposure to corticoster-
oids restores receptors to their previously sensitized 
state.83 Chronic LABA or SABA exposure will also 
lead to reduced β receptor numbers, as they are inter-
nalized and degraded; ICS reverse this effect because 
the activation of GRE causes gene transcription and 
hence synthesis of these receptors.84
The main RCTS for combination inhalers are 
shown in Table 6. A number of secondary analyses 
of TORCH data have also been published, detailing 
determinants of change in health status,85 beneficial 
effects on FEV1 decline,
86 and stratifying analysis for 
disease stage.87
Table 6. Major RCTs of ICS/LABA.
Trial Ics/LABA Duration Outcome comparator
Calverley et al23 Budesonide/ 
formoterol
1 year ↓ Exacerbations v P and F
↔ FEv1 v all
↑ HRQoL v all
Placebo, 
formoterol, 
budesonide
Szafranski et al33 Budesonide/ 
formoterol
1 year ↓ Exacerbations v P and F
↔ FEv1 v P and B
↑ HRQoL v P and B
Placebo, 
formoterol, 
budesonide
Calverley et al28  
(TRISTAN)
Salmeterol/ 
fluticasone
1 year ↑ FEv1 v all
↑ HRQoL v all
↓ Exacerbations v P
Placebo, 
salmeterol, 
fluticasone
Calverley et al29  
(TORCH)
Salmeterol/ 
fluticasone
3 years ↓ Exacerbations v all
↑ HRQoL v P
Placebo, 
salmeterol, 
fluticasone
wedzicha et al88  
(INSPIRE)
Salmeterol/ 
fluticasone
2 years ↔ Exacerbations
↑ HRQoL
↓ Mortality
↑ Pneumonia
Tiotropium
notes: The table shows all results for ICS/LABA. See also ICS and LABA sections for individual component results.
Abbreviations: P, placebo; F, formoterol; S, salmeterol; B, budesonide.
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Safety
The side effect profiles of LABA/ICS combinations 
are effectively the sum of their component parts, as 
described above. Similar to the use of ICS, the most 
significant adverse event is the risk of pneumonia with 
combination inhalers.89 The risk is significantly higher 
than placebo or LABA but not so when compared with 
ICS. A recent systematic review and indirect com-
parison of trials looking at Symbicort and Seretide 
suggests that the risk of pneumonia is greater with 
Seretide, perhaps due to overall elevation in steroid 
load. The caveat to this is that data from the TORCH 
trial had a large bearing on the overall findings.90
phosphodiesterase Inhibitors
Mechanism of action
Roflumilast is a selective phosphodiesterase 4 (PDE4) 
inhibitor; PDE4 is an enzyme which is expressed in 
many pro-inflammatory cells. The therapeutic effects 
of roflumilast are thought to be mediated via increased 
levels of cellular cAMP and include inhibition of 
microvascular leakage, inhibition of trafficking, 
release of cytokines, and chemokines from inflamma-
tory cells, and mild bronchodilation.91 Roflumilast has 
a high oral bioavailability and is largely protein bound 
(98%). Peak plasma concentrations occur within one 
hour, mean elimination half-life is 17 hours, and 
a steady state is achieved after 4 days. The major 
metabolic pathway for roflumilast elimination after 
oral administration is pyridine N-oxidation, with the 
formation of roflumilast N-oxide; this metabolite is 
an active compound with pharmacokinetics distinct 
from its parent compound. Peak plasma concentra-
tions occur after 4 hours and its elimination half is 
approximately 27 hours. Although the major elimi-
nation route for both the drug and its metabolite is 
the kidney, studies have shown that dose adjustment 
is not required in renal impairment.92 Other selective 
PDE4 inhibitors were developed and went through 
trials,93 but roflumilast is the only one currently on 
the market.
Theophylline is a non-selective phosphodi-
esterase inhibitor. Through the enzymatic inhibition 
of phosphodiesterase, levels of cAMP and cGMP are 
increased giving it its weak bronchodilator effect.94 
To achieve this, however, fairly high concentrations 
of theophylline are needed. Recent evidence has 
shown that theophylline has some anti-inflammatory 
action and maybe able to modulate inflammatory 
gene expression by its interaction with the histone 
deacetylase.76 Theophylline like Roflumilast has a 
high oral bioavailability. Peak plasma concentration 
occurs between 1 and 2 hours, and it has an elimi-
nation half-life of 8 hours.75,77 Metabolism is largely 
by the liver, whereby the drug undergoes hydroxyla-
tion, N-demethylation, and N methylation to various 
compounds.75,77 The main RCTs for PDE4 inhibitors 
are shown in Table 10. Roflumilast appears to work 
best in the subset of COPD patients who have chronic 
bronchitis.95 Despite widespread use, there have been 
few parallel group studies of oral theophyllines; the 
Cochrane review in 2002 included 20 relatively small 
crossover studies and concluded that there were mod-
erate beneficial effects on lung function, with the 
caveat that results may not be generalizable.96
Safety
Treatment-related adverse events were higher in the 
roflumilast treatment arms of the clinical trials in 
Table 7. Gastrointestinal side effects, namely weight 
loss and nausea, were the most common, followed 
by neuropsychiatric effects. Although dropout rates 
overall were similar between roflumilast and pla-
cebo, more patients in the roflumilast arm dropped 
out within the first few weeks. Theophylline has 
been used for a number of years in airway disease 
and still has a role in the management of COPD.1 The 
main adverse effects encountered include tachycar-
dia, nausea, and tremor. Unfortunately it has a nar-
row therapeutic index and drug monitoring should be 
undertaken at regular intervals. The propensity for 
theophylline to interact with other drugs is another 
drawback to its use.
Mucolytics
Mucus hypersecretion and resultant chronic cough 
can often be a feature of COPD. Mucolytics have been 
used to reduce sputum viscosity and to aid expecto-
ration; those most widely used are carbocysteine and 
N-acetylcysteine (NAC). Others include erdosteine 
and ambroxol. NAC and to a lesser extent carbo-
cysteine have antioxidant properties. The awareness 
that oxidative stress and the formation of reactive oxy-
gen species play a role in COPD, especially during 
exacerbations, has suggested that treatment with muc-
olytics may be able to influence exacerbation rates.102
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Carbocysteine is a blocked thiol derivative of the 
amino acid L-cysteine. While the mechanism of action 
is not completely understood, it has the ability to split 
glycoprotein bonds in mucus. In vitro studies also sug-
gest a mucoregulatory mechanism. Carbocysteine is 
well absorbed and peak serum concentration as achieved 
at between 1 and 1.7 hours after ingestion. Approxi-
mately 30%–60% of the drug is excreted unchanged in 
the urine. The fraction of the drug not excreted in this 
manner undergoes metabolism via varying pathways 
with great inter-individual variability.103
NAC is recognized as a mucolytic agent with direct 
and indirect antioxidant properties. It differs from 
carbocysteine in that it has a free thiol group capable 
of interacting with reactive oxygen species, leading 
to NAC disulfide as an end product. NAC’s indirect 
properties arise from its role as a glutathione precursor. 
It is rapidly absorbed following oral administration 
with peak plasma concentrations occurring between 
2 to 3 hours and has a plasma half-life of 6.3 hours. 
NAC undergoes mainly hepatic metabolism.104
The most recent systematic review of clinical 
effectiveness of mucolytics included 30 studies and 
demonstrated a small but significant reduction in exac-
erbations in treated patients with COPD.105 Mucolytic 
agents however do not seem to have any effect on 
lung function. One of the largest trials with the power 
to demonstrate this was undertaken by Decramer 
et al. The use of NAC had no effect on lung function 
in those with mild or more severe COPD; addition-
ally, mucolytics had no effect on HRQoL.106
Oxygen
Overt or relative hypoxia is one of the hallmarks of 
COPD, especially in the latter stages of the disease. 
Oxygen therapy to ameliorate this has been proven 
to be effective for patients who have severe resting 
hypoxia, and it is considered a prescription interven-
tion in many countries. Whilst it is beyond the scope 
of this article to review all evidence pertaining to 
oxygen in detail, some key points and major studies 
can be included.
The basis for LTOT (.15 hours daily) is 
derived from two landmark RCTs: the NOTT trial 
which compared 12 hour (nocturnal) and 24 hour 
oxygen therapy,107 and the MRC trial which 
 compared . 15 hour oxygen therapy to placebo.108 
The main outcome in both trials was improved sur-
vival in patients receiving oxygen for at least 15 hours 
daily, though this improved survival was not seen in 
the MRC trial until one year after the initiation of 
oxygen therapy. The NOTT trial also demonstrated a 
fall in mean pulmonary artery pressure (PAP). Whilst 
a fall in mean PAP was not shown in the MRC trial, 
increases in PAP seen in the control arm did not occur 
in the patients undergoing oxygen therapy. LTOT 
is indicated for patients in a clinically stable state 
who have PaO2 , 7.3 kPa (55 mmHg) or 7.3–8 kPa 
(55–60 mmHg) in the presence of pulmonary hyper-
tension, nocturnal hypoxia, or secondary polycythae-
mia when assessed on two separate occasions. Aside 
from LTOT, two other modes of oxygen therapy exist: 
ambulatory and short burst (SBOT); both have been 
reviewed relatively recently.109 Ambulatory oxygen 
is indicated in mobile patients who meet the LTOT 
criteria and is commonly considered in other COPD 
patients who exhibit exertional desaturation to less 
than 90%. SBOT criteria are poorly defined, and in 
general no benefits are seen;110 it should therefore be 
used only in a palliative setting.
Table 7. Major RCTs of phophodiesterase inhibitors.
Trial Drug Duration Outcome comparator
Zuwhallack et al97 Theophylline 12 weeks ↑ FEv1**
↓ Symptoms**
Salmeterol
Rabe et al98 Roflumilast 24 weeks ↑ FEv1
↓ Exacerbations
Placebo
Calverley et al99 Roflumilast 1 year ↑ FEv1
↓ Exacerbations*
Placebo
Calverley et al100 Roflumilast 1 year ↑ FEv1
↓ Exacerbations
Placebo
Fabbri et al101 Roflumilast 1 year ↑ FEv1 Placebo
notes: *In GOLD stage 4 patients only; **in combination with salmeterol.
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smoking cessation
Tobacco smoke is arguably the most important etio-
logical factor for the development of COPD in the 
developed world. The impact of continued smok-
ing and its cessation on lung function (FEV1) is well 
known and illustrated via the Fletcher-Peto Curve.111 
Despite the continued advances in pharmacothera-
pies for COPD, smoking cessation remains the best 
way to delay progression of COPD at all stages of the 
disease.
Over the last few years the neurochemical basis 
of nicotine addiction has been better understood; it is 
thought that the addictive properties of nicotine are a 
result of dopamine release mediated via stimulation 
of the alpha4beta2 nicotinic receptors.112 Currently, 
the most common therapeutic strategies employ the 
use of Varenicline, Bupropion, and Nicotine replace-
ment therapy (NRT). Varenicline is a selective nico-
tinic receptor partial agonist. It mimics the effects of 
nicotine on dopamine release in the nucleus accum-
bens when given alone but attenuates this response 
to a subsequent nicotine challenge and reduces nico-
tine self-administration.112 Bupropion inhibits the re- 
uptake of dopamine, noradrenaline, and serotonin in 
the central nervous system.112 During nicotine with-
drawal, levels of these neurotransmitters fall, leading 
to withdrawal symptoms. Therefore, in limiting re- 
uptake the symptoms of withdrawal are attenuated. 
All three modalities113–115 have proven to be effective 
compared to placebo in smoking cessation, with avail-
able evidence favoring the superiority of  Varenicline 
over Bupropion. There is limited direct evidence 
between Varenicline and NRT, and only a few het-
erogeneous trials comparing Bupropion to NRT; 
overall it is likely that both are superior to NRT.113–115 
Post-marketing surveillance has raised subsequent 
concerns about possible between Varenicline and sui-
cidal ideation, such that a recent systematic review 
(mainly of evidence in populations unselected for 
psychiatric disease) advised using it only with caution 
in patients with pre-existing psychiatric problems.116 
Conversely a recent RCT specific to schizophrenic 
patients found if effective and safe.117
Opiates
Despite optimal management of COPD with the 
above pharmacotherapies, dyspnoea can be prob-
lematic, especially in the advanced stages of the 
 disease process. It pervades all aspects of patients’ life 
leading to a detrimental effect on its quality;  opiates 
are widely used in a palliative setting to reduce the 
sensation of dyspnoea.118 Endogenous opioids might 
modulate dyspnoea by a reduction in ventilatory 
drive in response to carbon dioxide,119 hypoxia,119 and 
exercise.120 This decrease in respiratory effort may 
lead to a reduction in breathlessness. In addition, the 
sedative effect of opiates may reduce anxiety. The 
use of opiates to manage dyspnoea was the subject 
of a systematic review in 2002.121 This demonstrated 
a significant beneficial effect of oral and parenteral 
opiates over placebo. This benefit was also seen when 
the subgroup analysis for patients solely with COPD 
was undertaken. One of the major concerns and pos-
sibly barriers to opiate usage is respiratory depres-
sion, especially in opioid naive patients. However, 
when appropriately administered and monitored at 
lower doses, they do not appear to cause significant 
respiratory depression.122
Other potential pharmacotherapies
The multicomponent nature of COPD has meant that 
therapeutic strategies have been trialed in an attempt 
to gain additional benefit to the interventions outlined 
above. Ameliorating sequelae such as pulmonary 
hypertension (PH), improving nutrition, and trying 
to reduce systemic inflammation all have theoretical 
merits.
PH in COPD adversely affects survival and exer-
cise capacity. Although the use of oxygen therapy 
has a protective effect on the progression of PH in 
patients with advanced COPD, its use is limited to 
patients who meet the LTOT criteria. Vasoactive 
compounds used in primary PH (sildenafil, bosentan, 
and nitric oxide) have been investigated in COPD and 
are shown in Table 8. Since some trials have shown 
worse HRQoL in treated patients, these drugs are not 
used routinely, although trial periods to see if benefit 
is seen are sometimes employed in selected patients 
by specialist centers.123
Over the last few years a number of studies have 
shown a relationship between vitamin D deficiency and 
severe COPD, whereby its deficiency seems to corre-
late with the degree of airflow obstruction.129,130 Clearly 
on this basis it would seem reasonable to replenish 
vitamin D levels. In a yearlong RCT, Lehouck et al131 
used high dose vitamin D supplementation in patients 
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Table 8. RCTs of drugs for PH in COPD.
Trial Drug Duration Outcome comparator
vonbank et al124 Nitric oxide + oxygen 3 months ↓ PAP
↔ PaO2
Oxygen
Stolz et al125 Bosentan 3 months ↓ PaO2
↓ HRQoL
↔ 6MwT distance
Placebo
valerio et al126 Bosentan 18 months ↓ PAP*
↑ 6MwT distance*
Placebo
Rao et al127 Sildenafil 12 weeks ↓ PAP
↑ 6MwT distance
Placebo
Lederer et al128 Sildenafil 4 weeks per  
intervention
↔ 6MwT distance
↓ HRQoL
Placebo
notes: *Statistically significant improvement over baseline in treated patients; comparison between groups was not reported.
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Figure 4. Classifying disease severity by GOLD.
notes: Patients are categorised by the combination of severity of 
spirometric impairment (GOLD airflow) or exacerbations and mMRC 
or CAT. whilst it is recognised that spirometry or exacerbations and 
mMRC or CAT may result in different groups for some patients, GOLD 
recommends that treatment should be according to whichever method 
chosen results in the higher risk.
with COPD. However, no benefit in lung function or 
exacerbations was seen in the treatment arm, except in 
the severely deficient in whom supplementation would 
be indicated for other reasons. Some studies have used 
other forms of nutritional supplementation in the con-
text of pulmonary rehabilitation,132 albeit with limited 
benefits. Consequently, nutritional supplementation is 
not routinely used therapeutically in COPD.
Treatment Algorithms in cOpD
The updated GOLD guidance1 has made some 
changes to the way that the therapies detailed 
above are  recommended. Other national guidance 
(eg, British NICE guidance5) differs markedly in 
the order of which drugs are used. In order to inter-
pret the GOLD guidance, disease stage, symptoms, 
HRQoL and exacerbation frequency must all be taken 
into account; this is shown in Figure 4. Table 9 com-
pares the main differences between guidelines, some 
of which are described below.
First line treatment
The use of bronchodilators is central to the manage-
ment of COPD and, although not extensively dis-
cussed, the use of short acting agents are best used 
for rescue of symptoms. Both LAMAs and LABAs 
in the trials above were used across the full spectrum 
of disease severity and have all been shown to have 
significant effects on outcome measures in COPD. 
Consistent clinically and statistically significant 
improvements in lung function, HRQoL, and reduc-
tion in exacerbations in the region of 15%–20% have 
been demonstrated. International and national guide-
lines suggest that either a LABA or LAMA be used as 
maintenance therapy for GOLD2 disease. The choice 
of which agent depends on patient preference, toler-
ability, and cost.
Based on current evidence, tiotropium and inda-
caterol are essentially equivalent, with indacaterol 
being slightly more favorable at influencing HRQoL. 
The place of aclidinium and glycopyrronium is likely 
to be as an alternative to tiotropium or LABA. Thus, 
when it comes to prescribing maintenance therapy 
for patients with COPD, a trial of either indacaterol 
or tiotropium should be used in the first instance as 
they provide significantly better bronchodilation and 
reduce the risk of severe exacerbations.
Additions if remains symptomatic
The role of ICS in COPD is contentious. In most of 
the trials discussed, although FEV1 was superior to 
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 placebo the magnitude of improvement in FEV1 with 
ICS was inferior to that of the LABA used. TORCH 
was the only trial to show slower decline in FEV1 
against placebo when fluticasone was used as a mono-
therapy. What has been proven to be relatively con-
sistent is their ability to reduce exacerbations. This 
benefit is largely in patients with FEV1 , 50% (ie, 
GOLD ¾). The tradeoff for this benefit is an increased 
risk of local side effects and pneumonia. It is in these 
patients who suffer recurrent exacerbations that the 
risk benefit ratio is greatest. Their use in management 
of COPD cannot be advocated earlier as both LAMA 
and LABA monotherapy produce significant increases 
in lung function outcomes as well as a reduction in 
exacerbations. Current national guidelines in the 
UK do not suggest using ICS as monotherapy but in 
addition to a LABA; GOLD guidelines only recom-
mend ICS monotherapy used with a LAMA as a sec-
ond choice in patients with severe disease who suffer 
recurrent exacerbations and have poor functional 
capacity.
Whilst this section of the review focuses on the 
use of ICS in COPD, a growing body of evidence 
suggests that an overlap syndrome of COPD and 
asthma exists,133–136 although the syndrome is not 
clearly defined. However, the general consensus is 
that patients with incompletely reversible airflow 
obstruction exhibit sputum eosinophilia, history of 
atopy, and, following bronchodilator, either improve-
ment in FEV1 . 12% (200 mls), or improvement in 
FEV1 . 15% (400 mls). In this subset of patients 
ICS therapy may have greater benefit and should be 
employed earlier.135,136
Other options
The use of roflumilast in patients has been largely 
confined to GOLD3/4 disease. In most of the clinical 
trials patients were selected on the basis of chronic 
bronchitis, recurrent exacerbations requiring oral cor-
ticosteroids, or the need for hospital admission. Its 
use provided modest but significantly improved FEV1 
compared with placebo and a reduction in exacerba-
tion rates when used with a long acting  bronchodilator. 
International guidelines advocate its use as second line 
in GOLD 4 patients or as an adjunct to treatment in 
GOLD 3 patients who are already on LABA/ICS com-
bination inhalers. UK guidance advocates its use in 
GOLD3 patients with a history of recurrent bronchitis 
or exacerbations. The place of theophylline is seem-
ingly more variable. International guidelines advocate 
its use as an alternative to inhaled bronchodilators in 
mild disease, but also as an adjunct from moderate to 
very severe disease. UK guidelines only suggest its 
use after a trial of short or long acting bronchodila-
tors or in those who cannot tolerate inhaled therapy.
conclusion
The pharmacological management of COPD is driven 
by symptoms. As a progressive disease it is clear that 
over time increasing intervention will be required to 
manage symptoms appropriately. This review has 
outlined the key pharmacological treatments used. 
Table 9. Comparison of GOLD and UK NICE guidance for COPD management.
FeV1 GOLD  
category
GOLD 1st  
line
GOLD 2nd line nIce guidance
.50% A SABA/SAMA LAMA/LABA/SAMA/SABA
Theophylline
SAMA/SABA
LABA/LAMA
LABA+ICS*B LAMA/LABA LAMA+LABA
,50% C LABA+ICS/ 
LAMA
LAMA+LABA
PD4
Theophylline
LABA+ICS
LAMA+LABA
ICS+LABA+LAMA
D LABA+ICS/ 
LAMA
LAMA+LABA
ICS+LAMA
ICS+LABA+LAMA
ICS+LABA+PD4
LAMA+PD4
Theophylline
notes: First choice treatment shown in italics. *Only if persistent symptoms.
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Unfortunately however, no treatment has been shown 
conclusively to reduce mortality and very few slow 
the rate of decline in lung function in COPD. ICS have 
not proven to be as effective as in asthma and what 
benefits are derived need to be balanced against the 
increased risk of pneumonia. Since bronchodilators 
are the mainstay of current management the search 
to improve existing bronchodilators will continue; 
so also will the search for novel anti-inflammatory 
agents and therapeutic strategies to reverse the corti-
costeroid resistance seen in COPD.
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